NASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free SAGE Stock Alerts $14.00 +1.05 (+8.11%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$13.65▼$14.5250-Day Range$12.57▼$25.7552-Week Range$10.92▼$59.99Volume2.33 million shsAverage Volume1.02 million shsMarket Capitalization$841.54 millionP/E RatioN/ADividend YieldN/APrice Target$39.28 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sage Therapeutics alerts: Email Address Sage Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.12 Rating ScoreUpside/Downside181.8% Upside$39.28 Price TargetShort InterestBearish17.53% of Float Sold ShortDividend StrengthN/ASustainability-1.66Upright™ Environmental ScoreNews Sentiment-0.32Based on 32 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.30) to ($4.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.98 out of 5 starsMedical Sector137th out of 909 stocksPharmaceutical Preparations Industry48th out of 423 stocks 4.1 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on 3 buy ratings, 13 hold ratings, and 1 sell rating.Amount of Analyst CoverageSage Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.53% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 2.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 65.22% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.66. Previous Next 2.0 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Sage Therapeutics this week, compared to 5 articles on an average week.Search Interest7 people have searched for SAGE on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows4 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($6.30) to ($4.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Sage Therapeutics Stock (NASDAQ:SAGE)Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More SAGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAGE Stock News HeadlinesApril 24, 2024 | markets.businessinsider.comHere's what to expect from Sage Therapeutics's earnings reportApril 21, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Rating Lowered to Sell at StockNews.comApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 20, 2024 | americanbankingnews.comScotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $19.00April 20, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by Needham & Company LLCApril 20, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $17.00April 20, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $16.00April 20, 2024 | americanbankingnews.comWedbush Weighs in on Sage Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:SAGE)April 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 19, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Stock Rating Reaffirmed by HC WainwrightApril 19, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Rating Reiterated by WedbushApril 19, 2024 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Cut to Underperform at Bank of AmericaApril 18, 2024 | msn.comB of A Securities Downgrades Sage Therapeutics (SAGE)April 18, 2024 | markets.businessinsider.comIn-Depth Examination Of 9 Analyst Recommendations For Sage TherapeuticsApril 18, 2024 | americanbankingnews.comSage Therapeutics (SAGE) Scheduled to Post Earnings on ThursdayApril 17, 2024 | msn.comSage Therapeutics stock plunges 20 percent after Parkinson’s drug fails studyApril 17, 2024 | benzinga.comNeurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's DataApril 17, 2024 | msn.comBofA downgrades Sage to underperform, cites failed Parkinson's studyApril 17, 2024 | markets.businessinsider.comNasdaq Down Over 1%; Sage Therapeutics Shares PlungeApril 17, 2024 | finance.yahoo.comSage Stock Collapses To Record Low After Parkinson's Drug Misses Its MarkApril 17, 2024 | investors.comSage Therapeutics Hammered After Parkinson's Drug Misses The MarkApril 17, 2024 | marketwatch.comSage Therapeutics Stops Further Development of Dalzanemdor in Parkinson's DiseaseApril 17, 2024 | marketwatch.comSage Therapeutics Shares Sink Premarket After Setback in Development of DalzanemdorApril 17, 2024 | markets.businessinsider.comSage Therapeutics' Dalzanemdor Phase 2 Study Fails To Meet Primary EndpointApril 17, 2024 | reuters.comSage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage studyApril 17, 2024 | msn.comSage drops after mid-stage setback for Parkinson’s disease candidateApril 17, 2024 | finance.yahoo.comSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s DiseaseSee More Headlines Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/24/2024Next Earnings (Confirmed)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees487Year FoundedN/APrice Target and Rating Average Stock Price Target$39.28 High Stock Price Target$294.00 Low Stock Price Target$14.00 Potential Upside/Downside+180.6%Consensus RatingHold Rating Score (0-4)2.12 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($9.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-541,490,000.00 Net Margins-626.32% Pretax Margin-626.33% Return on Equity-54.41% Return on Assets-49.13% Debt Debt-to-Equity RatioN/A Current Ratio10.51 Quick Ratio10.51 Sales & Book Value Annual Sales$86.46 million Price / Sales9.73 Cash FlowN/A Price / Cash FlowN/A Book Value$13.32 per share Price / Book1.05Miscellaneous Outstanding Shares60,110,000Free Float56,801,000Market Cap$841.54 million OptionableOptionable Beta0.86 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Barry E. Greene (Age 61)President, CEO & Director Comp: $1.29MMs. Kimi E. Iguchi CPA (Age 62)CFO & Treasurer Comp: $665.37kMs. Anne Marie Cook Esq. (Age 62)Senior VP, General Counsel & Secretary Comp: $711.6kMr. Christopher Benecchi (Age 52)Chief Business Officer Comp: $703.76kDr. Laura Gault M.D.Ph.D., Chief Medical OfficerMr. Matt LasmanisChief Technology & Innovation OfficerMr. Mike QuirkChief Scientific OfficerAshley KaplowitzDirector of Investor RelationsMs. Erin E. Lanciani (Age 55)Chief People & Experience Officer Dr. Amy Schacterle Ph.D.Senior Vice President of R&D Strategy and Business ManagementMore ExecutivesKey CompetitorsALX OncologyNASDAQ:ALXOPliant TherapeuticsNASDAQ:PLRXArcturus TherapeuticsNASDAQ:ARCTEnliven TherapeuticsNASDAQ:ELVNOcular TherapeutixNASDAQ:OCULView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 143,075 shares on 4/24/2024Ownership: 0.261%Allspring Global Investments Holdings LLCSold 6,956 shares on 4/18/2024Ownership: 0.081%Hennion & Walsh Asset Management Inc.Bought 5,068 shares on 4/17/2024Ownership: 0.111%Healthcare of Ontario Pension Plan Trust FundBought 183,607 shares on 3/21/2024Ownership: 0.335%Vanguard Group Inc.Bought 111,358 shares on 3/11/2024Ownership: 8.850%View All Insider TransactionsView All Institutional Transactions SAGE Stock Analysis - Frequently Asked Questions Should I buy or sell Sage Therapeutics stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 1 sell rating, 13 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks. What is Sage Therapeutics' stock price target for 2024? 17 brokers have issued 12 month price targets for Sage Therapeutics' stock. Their SAGE share price targets range from $14.00 to $294.00. On average, they expect the company's stock price to reach $39.28 in the next year. This suggests a possible upside of 181.8% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts. How have SAGE shares performed in 2024? Sage Therapeutics' stock was trading at $21.67 at the beginning of 2024. Since then, SAGE stock has decreased by 35.7% and is now trading at $13.94. View the best growth stocks for 2024 here. When is Sage Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our SAGE earnings forecast. How can I listen to Sage Therapeutics' earnings call? Sage Therapeutics will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.73. The biopharmaceutical company had revenue of $77.97 million for the quarter, compared to the consensus estimate of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative trailing twelve-month return on equity of 54.41%. The company's revenue for the quarter was up 2621.5% compared to the same quarter last year. During the same quarter last year, the company posted ($2.47) EPS. What ETFs hold Sage Therapeutics' stock? ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) and Virtus LifeSci Biotech Products ETF (BBP).AdvisorShares Dorsey Wright Short ETF (DWSH). What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY). Who are Sage Therapeutics' major shareholders? Sage Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.26%), Hennion & Walsh Asset Management Inc. (0.11%) and Allspring Global Investments Holdings LLC (0.08%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas. View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SAGE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.